Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545410 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL380599 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL5161799 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29898350 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL380600 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9698824 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL574263 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL159553 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL159552 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| Water SCHEMBL23711627 | 0.98 | DPP4 (0.50) | DPP4MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| US-12515178-B1 | Grafted polyamide membrane for nanofiltration applications | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-06 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| EP-4554624-A1 | ANTIBODY-DRUG CONJUGATES | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| EP-1147129-A4 | SACCHARIDES LINKED TO COMPOUNDS THAT BIND CELL-SURFACE PEPTIDES OR PROTEINS | UNIV PRINCETON (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1147129-A1 | SACCHARIDES LINKED TO COMPOUNDS THAT BIND CELL-SURFACE PEPTIDES OR PROTEINS | Princeton University (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000042067-A1 | SACCHARIDES LINKED TO COMPOUNDS THAT BIND CELL-SURFACE PEPTIDES OR PROTEINS | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | claimed |
| US-5891621-A | IN SITU SCREENING OF MANY ENZYMES, ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | claimed |
| EP-0381706-A4 | A METHOD OF MAINTAINING A DESIRED RECOMBINANT GENE IN A GENETIC POPULATION OF CELLS | — | 1991-09-11 | — | — | EP | claimed |
| EP-0381706-A1 | A METHOD OF MAINTAINING A DESIRED RECOMBINANT GENE IN A GENETIC POPULATION OF CELLS. | UNIV WASHINGTON (US) | 1990-08-16 | — | — | EP | claimed |
| EP-0177882-B1 | ANTIBIOTIC A 40926 COMPLEX AND ITS PURE FACTORS PA, PB, A, B AND BO | GRUPPO LEPETIT S.p.A. (IT) | 1990-01-03 | — | — | EP | claimed |
| US-4888279-A | Novel immunosorbent assays employing antibiotic keying agents | THOMAS JEFFERSON UNIVERSITY (US) | 1989-12-19 | — | — | US | claimed |
| EP-0184615-B1 | SOLID PHASE RECEPTOR ASSAY FOR ANTIBIOTICS OF THE VANCOMYCIN CLASS | GRUPPO LEPETIT S.p.A. (IT) | 1989-07-26 | — | — | EP | claimed |
| WO-1989003427-A1 | A METHOD OF MAINTAINING A DESIRED RECOMBINANT GENE IN A GENETIC POPULATION OF CELLS | WASHINGTON UNIVERSITY (US) | 1989-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | DPP4 1262/4885MME 1501/4885ACE 1733/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | DPP4 4452/4885MME 3897/4885ACE 4784/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | DPP4 2235/4885MME 961/4885ACE 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.